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cyc--Variants of S49 lymphoma cells are defective in the stimulatory guanine nucleotide site of the 
adenylate cyclase but contain an inhibitory site. Treatment of cyc- cells with islet-activating protein (IAP), 
which causes ADP-ribosylation of an Mr 40000 polypeptide in cyc- membranes, abolishes adenylate 
cyclase inhibition by GTP and the peptide hormone, somatostatin, but not that induced by GTPyS. 
Furthermore, somatostatin-induced stimulation of GTP hydrolysis is lost. Thus, the data indicate that IAP 
interferes with the adenylate cyclase system by an action at the inhibitory guanine nucleotide site. 
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1. INTRODUCTION 
cyc--Variants of S49 lymphoma cells are defi- 
cient in the guanine nucleotide-binding regulatory 
site (N,) mediating adenylate cyclase stimulation 
by hormones, guanine nucleotides and cholera tox- 
in [l]. However, the cyc- adenylate cyclase can be 
inhibited by GTP and particularly by stable GTP 
analogs such guanosine 5 ’ -O- 
(3-thiotriphosphate) (gTP+) and guanyl 5’-yl- 
imidodiphosphate [2,3]. This finding suggested 
that the N,-deficient cyc- membranes contain a 
guanine nucleotide regulatory site (N,) mediating 
adenylate cyclase inhibition. The evidence for a Ni 
component in cyc- membranes has been cor- 
roborated by the finding that the cyc- adenylate 
cyclase is inhibited by the peptide hormone, 
somatostatin [4]. Similarly as described for hor- 
monal inhibition in various ‘complete’ cellular 
systems [5,6], the somatostatin-induced inhibition 
of cyc- adenylate cyclase is a GTPdependent pro- 
cess. Furthermore, somatostatin increases GTP 
hydrolysis in cyc- membranes due to stimulation 
of a high affinity GTPase [4]. 
Islet-activating protein (IAP), a Bordeteilu per- 
tussis toxin, catalyzes ADP-ribosylation of an Mr 
41000 polypeptide in various cellular systems 
[7-g]. The substrate for ADP-ribosylation by IAP 
is apparently composed of MI 41000 and 35000 
subunits and is able to bind guanine nucleotides 
[lo]. Since after IAP treatment the adenylate 
cyclase inhibition by hormones and GTP was im- 
paired, it has been suggested that IAP by its ADP- 
ribosylating activity somehow blocks the function 
of Nl[9]. S49 Lymphoma cyc- variants apparently 
containing only Ni but not Ns are, thus, an ideal 
system for testing the question of IAPs action in 
the adenylate cyclase system. We report here that 
IAP treatment of cyc- cells prevents somatostatin- 
induced adenylate cyclase inhibition and GTPase 
stimulation but not adenylate cyclase inhibition in- 
duced by the stable GTP analog, GTPyS. 
2. MATERIALS AND METHODS 
2.1. Materials 
IAP was purified to apparent homogeneity on 
hydroxyapatite columns and haptoglobulin- 
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Sepharose columns according to [l l] from the 
supernatant of Bordetella pertussis suspensions 
kindly provided by Drs L. Robbel and F. Black- 
kolb (Behringwerke, Marburg). Forskolin was 
donated by Dr H. Metzger (Hoechst AG, Frank- 
furt). Somatostatin and cholera toxin were obtain- 
ed from Sigma. [c~-“PINAD (50 Ci/mmol) and 
[i4C]methylated protein mixture as weight markers 
for gel electrophoresis were from Amersham- 
Buchler. Other materials were as in [3,4]. 
2.2. IAP treatment of S49 lymphoma cyc- cells 
S49 Lymphoma cyc- variants were grown in 
Dulbecco’s modified Eagle’s medium. Where in- 
dicated, the culture medium was fortified with 
20 ng IAP/ml to provide IAP-treated cells; the 
vehicle used for dissolving IAP [I l] was added for 
preparation of control cells. After 24 h treatment, 
membranes of IAP-treated and control cells were 
prepared as in [3]. Preparation of membranes of 
wild-type S49 lymphoma cells was done in an iden- 
tical manner. 
2.3. Radiolabelling 
Membranes of control cyc- variants and wild- 
type cells (-25Osg protein/tube) were incubated 
without and with 25 pg IAP/ml, 300/1g/ml of 
cholera toxin @reactivated for 10 min at 37°C 
with 25 mM dithiothreitol) or their combination 
for 30 min at 37°C in a reaction buffer containing 
1 PM [cY-~‘P]NAD (5-lO,&i/tube), 1 mM ATP, 
1 mM GTP, 5 mM MgC12, 10 mM thymidine, 
10 mM arginine, 5 mM creatine phosphate, 
0.4 mg creatine kinase/ml and 50 mM 
triethanolamine-HCl (pH 7.4) in 220 pl final vol. 
Thereafter, the membranes were pelleted and 
washed twice with 1 ml 10 mM triethanolamine- 
HCl (pH 7.4). Radiolabelled membranes were 
dissolved in 50~1 of a gel sample buffer (4Yo 
sodium dodecyl sulfate, 0.002% bromphenol blue, 
23% glycerol, 10% 2-mercaptoethanol, 62.5 mM 
Tris-HCl, pH 6.8) and heated for 5 min at 100°C. 
Aliquots (25 ~1) were subjected to dodecyl 
sulfate-polyacrylamide gel electrophoresis [12] on 
slab gels (1.5 mm thick), which consisted of a 8% 
separating gel and a 3% stacking gel. After elec- 
trophoresis, gels were stained with Coomassie 
brilliant blue, destained, dried and exposed to 
Kodak X-Omat AR-film for 48-96 h at -80°C. 
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2.4. Adenyiate cyclase and GTPase assays 
Adenylate cyclase activity was determined as in 
[4] with 50 PM [~u-‘~P]ATP (-0.4 &i/tube), 
100 pM MnClz, 0.1 mM cyclic AMP, 1 mM 
3-isobutyl-1-methylxanthine, 5 mM creatine phos- 
phate, 0.4 mg creatine kinase/ml, 1 mg bacitra- 
tin/ml, 2 mg bovine serum albumin/ml, 1OOpM 
forskolin and 50 mM triethanolamine-HCl (pH 
7.4) in 100 pl total vol. Reactions were initiated by 
the addition of cyc- membranes (20-3Opg pro- 
tein/tube) and conducted for 10 min at 30°C. 
Cyclic AMP formed was isolated as in [ 131. 
GTPase activity was determined as in [4] with 
0.5 PM [T-~~P]GTP (-0.1 &i/tube), 3 mM 
MgC12, 1 mM EDTA, 0.1 mM ATP, 1 mM adenyl 
5 ’ -yl-imidodiphosphate, 0.1 mM cyclic AMP, 
1 n&I 3-isobutyl-1-methylxanthine, 5 mM creatine 
phosphate, 0.4 mg creatine kinase/ml, 1 mg 
bacitracin/ml, 2 mg bovine serum albumin/ml and 
50 mM triethanolamine-HCl @H 7.4). Incubation 
with cyc- membranes (5-10 /rg protein/tube) was 
for 10 min at 30°C. Specific, low Km GTPase ac- 
tivity was determined as in [4]. 
3. RESULTS 
As described in [l], cholera toxin radiolabelled, 
in the presence of [(r-“PINAD, two polypeptides 
with Mr 43000 and 50000 in wild-type but not in 
cyc- membranes (fig. 1). In contrast, radiolabelling 
by IAP of a polypeptide with M, 40000 was 
observed in both wild-type and control cyc- mem- 
branes. Cholera toxin and IAP caused additional 
radiolabelling of polypeptides with Mr 21000 and 
27000, respectively, which appear to be auto- 
ADP-ribosylation products of subunits of the tox- 
ins [lo]. Thus, IAP radiolabels a polypeptide in 
cyc- membranes and the radiolabelling pattern is 
similar to that observed in various other cellular 
systems [7-lo]. Therefore, it was studied whether 
treatment of cyc- cells affects the adenylate cyclase 
and GTPase regulations by somatostatin. 
In the presence of 3 yM GTP, somatostatin 
caused a concentration-dependent decrease in 
100 pM forskolin-stimulated adenylate cyclase ac- 
tivity in membranes of control cyc- variants 
(fig.2). The inhibition was half-maximal at 
l-3 nM and maximal inhibition by -20% was 
observed at 30 nM somatostatin. In contrast, in 
membranes of IAP-treated cells, somatostatin, up 
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Fig.3. Polyacrylamide gel analysis of radioactive 
products resulting from IAP or cholera toxin-catalyzed 
ADP-ribosylation of control cyc- and wild-type S49 
lyrnphoma membranes. Membranes of untreated cyc- 
variants (CYC-, left) and wild-type S49 lymphoma cells 
(WT, right) were ~cubat~ w&out (CON) and with 
cholera toxin (CT), IAP or both as indicated in the 
presence of [w~~P]NAD. Thus labelled membranes were 
submitted to electrophoresis and autoradiography as in 
section 2. 14C-Labelled M,-markers (phosphorylase b, 
92500; bovine serum albumin, 69oo0, ovalbumin, 
46ooO; carbonic anhydrase, 3Ooo0, lysozyme, 14300) are 
shown in the middle lanes. 
to 1 PM, had no effect on adenylate cyclase activi- 
ty stimulated by forskolin. Similar data were ob- 
tained when the effect of somatostatin was studied 
on the high affinity GTPase activity. In mem- 
branes of control cyc” cells, somatastatin 
stimulated the high affinity GTPase by up to about 
35% (fig.3). Half-maximal and maximal stimula- 
tions of the GTPase were observed at concentra- 
tions of the hormone similar to thuse required for 
adenylate cyclase inhibition. Again, in membranes 
of IAP-treated cyc- cells, somatostatin had na ef- 
fect on the high affinity GTPase activity. 
The cyc” adenylate cyclase is not only inhibited 
by somatostatin. As shown before f&3], the en- 
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Fig.2. Influence of somatostatin on adenylate cyclase 
activity in m~br~es of control and TAP-treated cyc- 
cells, Adenylate cyclase activity was determined in 
membranes of control and IAP-treated cyc- cells 
without and with somatostatin at the indicated 
concentrations. Forskolin (1OOpM) and GTP (3rM) 
were present under each condition. Enzyme activity is 
given as % of control activity measured without 
somatostatin. Similar data were obtained in 3 separate 
expt. 
Table I 
Influence of IAP on cyc- adenylate cyclase inhibition by 
guanine nucleotides 
Additions Adenylate cyclase 
(pm01 CAMP, r&n-“. mg protein-‘) 
Control IAP 
None 152 f 5 142 f 6 
GTP (10,~M) 130 f 4 140 f 4 
GTPyS (0.1 PM) 98 f 4 94 f 5 
GTP + GTP+ 127 f 6 140 f 5 
Adenylate cyclase activity was determined in membranes 
of control and IAP-treated cyc- variants without and 
with GTP and GTPyS as indicated after a 10 min 
preincubation period with all reagents present except for 
labelled ATP. Forskolin (1OOpM) was present under 
each condition. Mean f SEM of triplicates are given 
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Fig.3. Influence of somatostatin on high affinity 
GTPase activity in membranes of control and IAP- 
treated cyc- cells. GTPase activity was determined in 
membranes of control and IAP-treated cyc- cells 
without and with somatostatin at the indicated 
concentrations. High affinity GTPase activity estimated 
as in [4] is given on the ordinate. Similar data were 
obtained in 3 separate expt. 
zyme can also be inhibited by GTP and by stable 
GTP analogs. Therefore, it was studied whether 
IAP treatment affects the enzyme inhibition by 
these guanine nucleotides. In control membranes, 
GTPyS (0.1 ,uM) decreased the forskolin- 
stimulated activity by -35% (table 1). GTP, which 
is less potent and less efficient than GTPyS [2,3], 
caused a decrease in activity by only - 15% at 
10pM. In membranes of IAP-treated cells, the 
small inhibition induced by GTP was abolished. 
However, the inhibition induced by GTPyS was 
largely unaffected in IAP-treated membranes. Fur- 
thermore, GTP antagonized the GTPyS-induced 
inhibition both in membranes of control and IAP- 
treated cells. Similar data with regard to 
radiolabelling by IAP and to the effects of IAP on 
cyc- adenylate cyclase inhibition by GTP and a 
stable GTP analog have been reported [14]. 
4. DISCUSSION 
Membranes of cyc- variants of S49 lymphoma 
cells are deficient in the stimulatory guanine 
nucleotide site, N, [l], but these membranes ap- 
parently contain the inhibitory guanine nucleotide 
site, Ni [2-41. This site appears to mediate cyc- 
adenylate cyclase inhibition by GTP, stable GTP 
analogs and the peptide hormone, somatostatin. 
The Bordetella pertussis toxin, IAP, which has 
been shown to cause an ADP-ribosylation of an M, 
41000 polypeptide in various membrane systems 
[7-lo], also radiolabels in the presence of 
[w”P]NAD a polypeptide with a similar M, in 
cyc- membranes [14] (fig.1). Functional studies 
performed with IAP-treated N,- and Ni-containing 
cells suggested that the toxin causes a loss of 
receptor-mediated and GTP-dependent adenylate 
cyclase inhibition by affecting the involved coupl- 
ing component, Ni [9]. Therefore, the influence of 
IAP was studied on adenylate cyclase inhibition by 
GTP, the stable GTP analog, GTP+, and by 
somatostatin in N,-deficient cyc- membranes and 
on somatostatin-induced stimulation of a high af- 
finity GTPase in these membranes. 
These data show that treatment of cyc- cells 
with IAP abolishes the GTP-dependent, 
somatostatin-induced adenylate cyclase inhibition 
(fig.2). Furthermore, IAP treatment prevented the 
hormone-induced stimulation of a high affinity 
GTPase in cyc- membranes (fig.3). In membranes 
of neuroblastoma x glioma hybrid cells [15] and 
rat adipocytes [16], hormonal stimulation of the 
GTPase was also abolished after IAP treatment. 
Thus, IAP by its ADP-ribosylating activity ap- 
pears to induce a loss of the function of Ni. Similar 
to cholera toxin, causing an inhibition of N,- 
associated GTPase stimulation [17], IAP appears 
to exert its effect by inhibition of Ni-associated 
GTP hydrolysis. In contrast to cholera toxin, 
however, which amplifies the effects of GTP and 
stimulatory hormones at N, [17], the IAP-induced 
inhibition of GTP hydrolysis at Ni was not accom- 
panied by an increased inhibition of adenylate 
cyclase by GTP or an inhibitory hormone. On the 
contrary, IAP abolished their effects. These data 
suggest that  GTP hydrolysis step is involved in 
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Ni-mediated adenylate cyclase inhibition. 
However, the cyc- adenylate cyclase inhibition in- 
duced by stable GTP analogs was not affected by 
the IAP treatment [14] (table 1). 
There are several possibilities for explanation of 
these apparently contradictory results: 
(0 
(ii) 
Stable GTP analogs may induce cyc- 
adenylate cyclase inhibition by a mechanism 
not involving Ni, which mediates GTP and 
somatostatin-induced inhibition. However, 
the data reported so far suggest that stable 
GTP analogs and GTP interact at one 
regulatory site [2,3]. 
IAP treatment may prevent the binding of 
GTP but not that of GTPyS at Ni. This 
possibility could explain both the loss of 
adenylate cyclase inhibition by GTP and 
somatostatin and the loss of GTPase stimula- 
tion by the hormone. However, the IAP treat- 
ment did not abolish the competitive type of 
interaction between GTP and GTPyS (table 
l), suggesting that the binding of GTP is not 
affected by IAP. 
(iii) Whereas GTP hydrolysis is somehow required 
for Ni-mediated adenylate cyclase inhibition 
by GTP and somatostatin, stable GTP analogs 
may induce a conformational alteration of Ni, 
which is not affected by IAP and which leads 
to a persistent adenylate cyclase inhibition. It 
is not yet clear what the role of GTP 
hydrolysis is in Ni-mediated adenylate cyclase 
inhibition. This GTP hydrolysis may provide 
free energy for driving a cycle, but it may also 
represent a rapid phosphorylationdephos- 
phorylation reaction involved in GTP and 
hormone-induced adenylate cyclase inhibi- 
tion. 
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